Cargando…

978. Changes in BMI Associated with Antiretroviral Regimens in Treatment-Experienced, Virologically Suppressed Individuals Living with HIV

BACKGROUND: A potential association between integrase inhibitor (INSTI) use and weight gain has been reported in people living with HIV (PLWH). We examined body mass index (BMI) increases after a switch to dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), raltegravir (RAL), rilpivirine (RPV), or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mounzer, Karam, Brunet, Laurence, Hsu, Ricky, Fatukasi, Terra, Fusco, Jennifer S, Vannappagari, Vani, Henegar, Cassidy, van Wyk, Jean A, Crawford, Melissa, Lo, Janet, Fusco, Gregory
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809375/ http://dx.doi.org/10.1093/ofid/ofz359.080

Ejemplares similares

Two‐drug antiretroviral regimens: an assessment of virologic response and durability among treatment‐experienced persons living with HIV in the OPERA(®) Observational Database
por: Pierone, Gerald, et al.
Publicado: (2019)

341. Risk of Type 2 Diabetes Mellitus after Antiretroviral Therapy Initiation in Individuals Living with HIV in the United States
por: Hsu, Ricky, et al.
Publicado: (2019)

1284. Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens
por: Pierone, Gerald, et al.
Publicado: (2022)

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA(®) observational database: a cohort study
por: Mounzer, Karam, et al.
Publicado: (2019)

Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes
por: Hsu, Ricky K., et al.
Publicado: (2023)

Antiretroviral therapy and liver disorders in the OPERA(®) cohort
por: Wohlfeiler, Michael, et al.
Publicado: (2020)

886. The Impact of the COVID-19 Pandemic on Clinical Follow-Up, Monitoring and Regimen Discontinuation for People Living with HIV in the US
por: Pierone, Gerald, et al.
Publicado: (2021)

1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA(®) Cohort
por: Sension, Michael, et al.
Publicado: (2023)

Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice
por: Lackey, Philip, et al.
Publicado: (2016)

2487. Low Rate of Virologic Failure in Antiretroviral Experienced Patients Prescribed Once Daily Raltegravir
por: Hsu, Ricky, et al.
Publicado: (2019)

936. Body Fat Redistribution/Accumulation, Pancreatic Disorders, Musculoskeletal Disorders, IRIS, Severe Systemic Rash and Hypersensitivity Reactions Following Initiation of Commonly Prescribed Antiretrovirals
por: Lackey, Philip, et al.
Publicado: (2018)

1265. Effectiveness and Durability of Dolutegravir (DTG)-Based Regimens in Older People Living with HIV (PLWH) from the Veterans Aging Cohort Study (VACS)
por: Yan, Lei, et al.
Publicado: (2022)

1028. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA(®) Cohort
por: Hsu, Ricky K, et al.
Publicado: (2023)

Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens
por: Mounzer, Karam, et al.
Publicado: (2022)

Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B*5701 Screening as a Risk‐Mitigation Measure
por: Stainsby, Chris M., et al.
Publicado: (2018)

2483. Characteristics and Outcomes Over First 12 Months of a Two-Drug Regimen (Dolutegravir/Rilpivirine) for Treatment of HIV-1 in the United States
por: Pierone, Gerald, et al.
Publicado: (2019)

1582. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year
por: Sension, Michael G, et al.
Publicado: (2022)

Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups
por: Rawlings, M Keith, et al.
Publicado: (2022)

1592. Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine Among People with HIV with Detectable Viral Loads at Initiation: Trio Cohort Study
por: Elion, Rick A, et al.
Publicado: (2023)

77. Risk of Virologic Failure Among Treatment-experienced Suppressed People with HIV (PWH) Treated with Single-Tablet 2-Drug (2DR) vs 3-Drug (3DR) Regimens
por: Sax, Paul, et al.
Publicado: (2021)

Weight gain before and after switch from TDF to TAF in a U.S. cohort study
por: Mallon, Patrick WG, et al.
Publicado: (2021)

Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review
por: Llibre, Josep M, et al.
Publicado: (2022)

2488. Virologic Failure in ART Naïve Patients Initiating on a Dolutegravir or Elvitegravir-Based Regimen
por: Wohlfeiler, Michael, et al.
Publicado: (2019)

Duration of antiretroviral regimens in treatment-experienced patients in clinical practice
por: Vilaplana, Vicente Escudero, et al.
Publicado: (2010)

Cryptococcal Antigenemia in Human Immunodeficiency Virus Antiretroviral Therapy–Experienced Ugandans With Virologic Failure
por: Mpoza, Edward, et al.
Publicado: (2019)

Risk factors for delayed antiretroviral therapy initiation among HIV-seropositive patients
por: Fatukasi, Terra V., et al.
Publicado: (2017)

Virological Failure and Acquired Genotypic Resistance Associated With Contemporary Antiretroviral Treatment Regimens
por: Rhee, Soo-Yon, et al.
Publicado: (2020)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV
por: Correa, Analú, et al.
Publicado: (2020)

Psychiatric Symptoms in Patients Receiving Dolutegravir
por: Fettiplace, Anna, et al.
Publicado: (2017)

Time to virologic failure for patients taking their first antiretroviral regimen and the subsequent resistance profiles
por: Crouzat, Frederic, et al.
Publicado: (2014)

1023. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability
por: Pierone, Gerald, et al.
Publicado: (2023)

Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d’Ivoire West Africa
por: Tchounga, Boris K., et al.
Publicado: (2020)

Fitness Cost of Antiretroviral Drug Resistance Mutations on the pol Gene during Analytical Antiretroviral Treatment Interruption among Individuals Experiencing Virological Failure
por: Hunter, James R., et al.
Publicado: (2021)

2502. Impact of Pharmacist-Led Antiretroviral Therapy Simplification Initiative in Heavily Treatment-Experienced Patients on Virologic Control
por: Jimenez, Humberto R, et al.
Publicado: (2019)

549. Weight and BMI Changes in HIV-Infected Virologically Suppressed Adults after Switching to an Elvitegravir- or Dolutegravir-Containing Regimen
por: Gibson, Amanda, et al.
Publicado: (2018)

Virologic Response to Tipranavir-Ritonavir or Darunavir-Ritonavir Based Regimens in Antiretroviral Therapy Experienced HIV-1 Patients: A Meta-Analysis and Meta-Regression of Randomized Controlled Clinical Trials
por: Berhan, Asres, et al.
Publicado: (2013)

Validation of the Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) chronic kidney disease risk score in HIV‐infected patients in the USA
por: Mills, AM, et al.
Publicado: (2020)

Adherence to contemporary antiretroviral treatment regimens and impact on immunological and virologic outcomes in a US healthcare system
por: T. Tchakoute, Christophe, et al.
Publicado: (2022)

1951. Guiding COVID-19 Booster Vaccinations by COVID-19 Quantitative Spike Ig Antibody Titers Regardless of HIV Status, Immunosuppression, and Age
por: Hsu, Ricky K, et al.
Publicado: (2022)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8e6c1dp0o3hf4608edqdde87oo